Daniela S Thommen
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 2023; 4:1395.
Sep 1, 2023Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Sep 1, 2023Nat Cancer 2023; 4:1395
Váraljai Renáta, Zimmer Lisa, Al-Matary Yahya, Kaptein Paulien, Albrecht Lea J, Shannan Batool, Brase Jan C, Gusenleitner Daniel, Amaral Teresa, Wyss Nina, Utikal Jochen, Flatz Lukas, Rambow Florian, Reinhardt Hans Christian, Dick Jenny, Engel Daniel R, Horn Susanne, Ugurel Selma, Sondermann Wiebke, Livingstone Elisabeth, Sucker Antje, Paschen Annette, Zhao Fang, Placke Jan M, Klose Jasmin M, Fendler Wolfgang Peter, Thommen Daniela S, Helfrich Iris, Schadendorf Dirk, Roesch Alexander
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 2023; 4:1292-1308.
Jul 31, 2023Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Jul 31, 2023Nat Cancer 2023; 4:1292-1308
Váraljai Renáta, Zimmer Lisa, Al-Matary Yahya, Kaptein Paulien, Albrecht Lea J, Shannan Batool, Brase Jan C, Gusenleitner Daniel, Amaral Teresa, Wyss Nina, Utikal Jochen, Flatz Lukas, Rambow Florian, Reinhardt Hans Christian, Dick Jenny, Engel Daniel R, Horn Susanne, Ugurel Selma, Sondermann Wiebke, Livingstone Elisabeth, Sucker Antje, Paschen Annette, Zhao Fang, Placke Jan M, Klose Jasmin M, Fendler Wolfgang Peter, Thommen Daniela S, Helfrich Iris, Schadendorf Dirk, Roesch Alexander
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Trefny M, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K, Zippelius A, Geier F, Thommen D, Rothschild S, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M, Berner F, Kashyap A, Kaiser M, Herzig P, Poechtrager S, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clin Cancer Res 2019; 25:3026-3034.
Feb 14, 2019A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Feb 14, 2019Clin Cancer Res 2019; 25:3026-3034
Trefny Marcel P, Savic Spasenija, Jermann Philip, Alborelli Ilaria, Schaub Stefan, Stenner Frank, Früh Martin, Trajanoski Zlatko, Flatz Lukas, Mertz Kirsten D, Zippelius Alfred, Geier Florian, Thommen Daniela S, Rothschild Sacha I, Uhlenbrock Franziska, Rieder Dietmar, Kasenda Benjamin, Stanczak Michal A, Berner Fiamma, Kashyap Abhishek S, Kaiser Monika, Herzig Petra, Poechtrager Severin, Läubli Heinz